Short report: Does the 6-minute walk test in hospitalized COPD patients exclusively correlate with lung function parameters or should psychological factors also be taken into account?

Michèle Borgmann¹,²*, Martina Ivanda³*, Yalda Hadizamani¹,², Markus Mohaupt⁴, Robert Bals⁵, Rudolf Lucas⁵,⁶, Jürg Hamacher¹,²‡, Volker Köllner⁷,⁸‡

¹ Internal Medicine and Pneumology, Lindenhofspital, Bern, Switzerland, ² Lungen- und Atemstiftung Bern, Bern, Switzerland, ³ MediClin Rose Clinic, Horn-Bad Meinberg, Germany, ⁴ Internal Medicine, Sonnenhofspital Bern, Bern, Switzerland, ⁵ Internal Medicine V—Pneumology, Allergology, Respiratory and Environmental Medicine, Faculty of Medicine, Saarland University, Homburg/Saar, Germany, ⁶ Division of Pulmonary Medicine, Vascular Biology Center, Medical College of Georgia, Georgia Regents University, Augusta, GA, United States of America, ⁷ Department of Behavioral Therapy and Psychosomatic Medicine, Rehabilitation Center Seehof, Federal German Pension Agency, Teltow, Germany, ⁸ Department of Psychosomatic Medicine, Psychosomatic Rehabilitation Research Group, Center for Internal Medicine and Dermatology, Charité—Universitätsmedizin, Berlin, Germany

* These authors also contributed equally to this work.
‡ These authors also contributed equally to this work.

Abstract

The 6-minute walk test is generally considered a standard test for the evaluation of short-term maximal physical performance. It has not been evaluated whether psychological factors, such as anxiety or depression, affect the performance or the results of the test. The main aim of this study was to investigate whether a correlation exists between psychological factors and the data from the 6-minute walking test. The study cohort consisted of 85 ♂= 34 and ♂= 51) 66 ± 10 (mean ± SD) year-old patients with chronic obstructive pulmonary disease (COPD) hospitalized for disease exacerbation. Forced Expiratory Volume in the first second (FEV₁) (% predicted) as predictor for lung function, as well as anxiety and depression symptoms assessed using the Hospital Anxiety and Depression Scale (HADS) as psychological predictors were collected. Bivariate correlations and hierarchical linear regression models were used to analyse the correlations. Walking distance was on average 260m ± 107m and ranged from 64m to 480m. HADS was negatively correlated with 6-min walking distance (r = 0.441, p = .0009, r = -.523, p = 00006). Hierarchical linear regression showed that FEV₁ alone explained 33%, and together with the psychological variables anxiety and depression explained 42% of the variance of results from the 6-minute walking test. These findings demonstrated that 11% of the data correlated with the psychological variables alone (p = .011). The effect size for lung function (f² = .717) and psychological variables (f² = .352) were high, whereas the socio-demographic variables sex, age, educational level and BMI could not explain any additional variance in our cohort. In conclusion, our
study indicates that psychological factors such as symptoms of depression and anxiety are associated with lower physical functional performance in the 6-minute walking test. As such, these factors should also be assessed. Future research is needed to show if treatments of anxiety and depression can improve the walking distance in COPD patients.

Introduction

The 6-minute walking test is a submaximal exercise test for assessing physical endurance, including main cardiovascular, pulmonary and neuro-musculoskeletal performance. The aim of the test is to evaluate exercise performance including the effect of medical interventions such as rehabilitation, cardiac bypass interventions, pulmonary lung volume reduction surgery, or drug treatment by walking a maximal distance in 6 minutes [1, 2]. Due to its simplicity, the test is closely related to daily life activities. Its broad applicability allows for the inclusion of frail and elderly patients. As such, the 6-minute walking test mainly reflects physical performance for everyday activities. Consequently, results from the test are often used as a clinical outcome parameter or as a biomarker associated with disease burden and all-cause mortality [3–8]. Although most frequently used in COPD patients, the test can also be applied to patients with interstitial lung disease, pulmonary hypertension and heart failure, as well as in neurologic patients.

COPD patients have a lower 6-minute walking distance than healthy individuals [9], which correlates with their morbidity and mortality [10–13]. A 6-minute walking distance below 350 meters or a decline of 30 m or more over 1 year was associated with significantly higher mortality in COPD patients [10, 14, 15]. In long-term, prospectively studied cohorts, the 6-minute walking distance in patients with severe COPD continued to decrease over time, while FEV$_1$ [16] changed much less or not at all [17]. As such, key lung functional parameters such as FEV$_1$ or the ratio of residual volume to total lung capacity (RV/TLC) have limitations as predictors for the course of COPD. This suggests that the 6-minute walking test can be considered as a reliable prognostic indicator to predict mortality and morbidity in COPD patients but that, apart from lung function parameters, also other measurements should be taken into account [18, 19].

Several factors including actual physical activity and exercise amount [20], sex [21], body composition [22], severity of dyspnea [23], extent of emphysema [24] and exacerbation history [25] were proposed to influence the 6-minute walking test in COPD patients. Besides deconditioning, more advanced systemic involvement may influence the test, as worsening apoptosis in muscle biopsies [26] and increased levels of markers of oxidative stress and inflammation were described in more severe COPD patients [27]. Moreover, increased comorbidity was demonstrated to add to the 6-minute walking distance decline over time [17]. The focus of these studies was mainly on demographic and somatic factors. A study by Ingle et al., 2006 including a cohort of 571 patients with heart failure and 688 control patients demonstrated for the first time that, in addition to demographic and somatic predictors, also psychological predictors such as self-reported anxiety and depression can be associated with the 6-minute walking distance [28]. The authors assessed anxiety and depression by 6-item Likert scales, but not by standardized tools. Therefore, a limitation of their study was that no robust conclusions on the influence of psychological factors on 6-minute walking distance could be drawn. Another study with healthy volunteers showed correlations between the 6-minute walking distance and the psychological component of quality of life [29].
The identification of psychological predictors has potential for the promotion of improved functional performance. While demographic characteristics cannot be influenced and somatic characteristics are difficult to influence, anxiety and depression can be mitigated through available treatments. Based on the findings described above, the aim of the present study was to assess the relationship between the 6-minute walking test and anxiety and depression symptoms, using for the first time standardized measurements in COPD patients. The results of the study suggest that, in addition to the somatic component of physical functioning, also predictive psychological variables should also be taken into account in the 6-minute walk test in patients with COPD.

Materials and methods

Sample

The study involved 85 (♀ = 34 and ♂ = 51) 66 ± 10 (mean ± SD) year-old COPD patients devoid of other important comorbidities that were mainly hospitalised for either a COPD exacerbation or pneumonia, and that had a 6-min walk assessment before discharge. Only patients assumed as having as principal and unique disease of clinical importance COPD were included. Patients with “important comorbidity”, including severe heart failure or severe rheumatologic disease were excluded from the study. This setting is the most frequent setting of performing 6-minute walk test in COPD patients worldwide. The studied patient cohort in this psychosomatic study in COPD patients included all hospitalised COPD patients [30]. All patients fulfilled at least the criteria for GOLD stage II (defined by FEV1 ≥ 50% but < 80%), due to the fact that there were only COPD patients requiring hospitalisation, which virtually eliminated mild disease situations. 33 patients were assigned to GOLD stage II (classified as “moderate”), 25 to GOLD stage III (classified as “severe” and defined by FEV1 ≥ 30% but < 50%), and 27 to GOLD stage IV (classified as “very severe”, with FEV1 < 30%) [31]. The study was approved by the Ethics Committee (KEK-No. 003/11) of the University of Bern in Switzerland. All patients were above the age of 18 years, with ages ranging from 41 to 83 years. The majority of the patients had finished elementary school. The consent to participate was by verbal consent given to the investigator (T.L.) and the date range was from 2007–2010.

Measuring instruments

The 6-minute walk test allows physical performance to be evaluated by measuring the distance walked on level terrain over a certain timeframe and was conducted according to a standardized protocol using the guidelines of the American Thoracic Society [3, 32].

As a lung function predictor, FEV1, the volume exhaled in one second during a forced expiration started at the level of total lung capacity (TLC) was measured by spirometry. As psychological predictor, the anxiety and depression symptoms were measured by the Hospital Anxiety and Depression Scale (HADS). HADS is the most widely used questionnaire internationally for assessing these symptoms, especially in patients with somatic diseases. The subscales HADS-anxiety and HADS-depression range is from 0 to 21. Values below 7 are normal, values from 8 to 10 are marginal, values from 11 to 14 indicate severe symptoms and values from 15 to 21 indicate very severe symptoms [33, 34].

In addition, sociodemographic data (age, gender, educational level, measured from 1 = no graduation to 5 = university degree), the body mass index (BMI calculated as weight indicated in kg / (height)^2 where height is indicated in m), the “body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic pulmonary disease” (BODE index) and the modified British Medical Research Council dyspnea index (mMRC) were recorded. The BODE index is a multidimensional prognostic 10-point scale growing beyond lung function,
where a higher result is associated with a higher risk of death from COPD [35]. The mMRC is a classification of dyspnea for COPD patients, which ranges from 0–4. The higher the degree, the more severe the shortness of breath [36].

**Statistical analyses**

Means and standard deviations for all normally distributed variables and the median and percentile for variables that are categorically or not normally distributed were computed for the whole sample and also separately for the three GOLD stages. To identify correlations between the 6-minute walk test and the somatic (BMI, FEV1, BODE Index, mMRC) and psychological (HADS-depression, HADS-anxiety) variables, product-moment correlations according to Pearson were calculated. In addition, the predictors for the 6-minute walk test were determined using hierarchical linear regressions.

In addition, a hierarchical linear regression was performed to analyse whether the psychological factors, in addition to the lung function variable FEV1, can explain part of the variance of the 6-minute walk test, whereby the lung function FEV1 was included in the first block and the psychological predictors, HADS-anxiety and HADS-depression, in the second block. Sociodemographic variables were included in a third block. Furthermore, using the backward selection the independent explanatory value of the HADS subscales on the 6-minute walking distance was enabled to determine.

Data analysis was done using IBM SPSS Statistics 24.0. The critical value for statistical significance was defined as \( p < .05 \) [37]. The standardized regression coefficients can be interpreted as effect variables following the correlation coefficients. According to Cohen, \(\beta \geq .10\) corresponds to a weak effect, \(\beta \geq .30\) to a moderate effect and \(\beta \geq .50\) to a strong effect [38]. In addition, the effect sizes \(f^2\) were calculated according to Cohen (1992)[39], which can be interpreted as follows: \(f^2 \geq .02\) weak effect, \(f^2 \geq .15\) moderate effect and \(f^2 \geq .35\) strong effect.

**Results**

**Descriptive statistics of somatic and pulmonary function variables**

The investigated patients had an average BMI of 25.7 kg/m² ± 5.9 kg/m². FEV1 was 44% ± 19%. The examined patients reached on average 260 ± 107 meter, with the shortest distance 64 meters and the longest 480 meters (median = 276m). The median of the BODE index was 3.0 (P10 = 0.6, P90 = 5.2) (0 = best value to 10 = worst value) and the one of the modified Medical Research Council degree of dyspnea was 2.0 (P10 = 0, P90 = 3) (0 = dyspnea during heavy exertion up to 4 = dyspnea during dressing/undressing). Table 1 shows the results of the somatic and pulmonary function as well as the demographic variables (gender and age) for the three GOLD stages.

**Descriptive statistics of psychological variables**

The mean of HADS-anxiety was 8.0 ± 4.6 and of HADS-depression 7.9 ± 5.0. Overall, 46.2% of participants had a value higher than 7 on the anxiety and depression scale. In more detail, in HADS-anxiety 43 persons (53.8%) showed normal (inconspicuous), 10 persons (12.6%) marginal and 27 persons (33.6%) conspicuous values, which indicates severe to very severe symptoms. A similar pattern is found for HADS-depression: 43 persons (53.8%) have normal (inconspicuous), 11 persons (13.8%) marginal and 26 persons (32.4%) conspicuous values, which also indicates severe to very severe symptoms. The two subscales show high reliability with a Cronbach’s alpha of \(\alpha = .81\) (HADS-anxiety) and \(\alpha = .87\) (HADS-depression). Table 1 shows the means and standard deviations of the HADS subscales for the three GOLD stages.
Table 2 demonstrates that no further important relationships between variables could be observed.

**Correlation between psychological variables and the 6-minute walk test**

HADS-anxiety ($r = -.44$, $p = .0009$) and HADS-depression ($r = -.52$, $p = .00006$) showed moderate negative correlations with the 6-minute walking test: The stronger the anxiety and depression symptoms in a patient, the shorter the walking distance within 6 minutes. Further correlations with demographic and pulmonary function variables are shown in Table 2.

The hierarchical linear regression showed that FEV$_1$ and the psychological variables HADS-anxiety, and HADS-depression together accounted for 42% of the variance of the 6-minute walk test, with 11% of these related to the psychological variables alone ($p = .011$).

Table 1. Means, standard deviations or median and percentile of the demographic variables, somatic, pulmonary function and HADS variables of the 85 hospitalized COPD patients without major comorbidities separated for the three GOLD stages.

|                | GOLD II (n = 33) | GOLD III (n = 25) | GOLD IV (n = 27) |
|----------------|------------------|-------------------|------------------|
| Gender         | 11 female, 22 male | 7 female, 18 male  | 16 female, 11 male |
| Age (years)    | 68.7 ± 8.5       | 66.8 ± 11.0       | 60.8 ±8.0        |
| BMI (kg/m$^2$) | 27.7 ± 6.6       | 25.7 ± 5.5        | 25.8 ± 5.8       |
| FEV$_1$ (%)    | 64.6 ± 8.5       | 40.0 ± 6.5        | 22.0 ±4.8        |
| 6-min-distance (m) | 355 ± 58 | 254 ± 93         | 206 ± 103        |
| BODE index     | 3.0 ($P_{10} = 0.6$, $P_{90} = 5.2$) | 5.0 ($P_{10} = 3$, $P_{90} = 9$) | 7.0 ($P_{10} = 5$, $P_{90} = 9$) |
| mMRC           | 2.0 ($P_{10} = 0$, $P_{90} = 3$) | 2.0 ($P_{10} = 1$, $P_{90} = 4$) | 3.0 ($P_{10} = 2$, $P_{90} = 4$) |
| HADS-anxiety   | 5.7±4.4          | 8.4±3.9           | 10.2±4.4         |
| HADS-depression| 5.5±4.4          | 9.1±4.8           | 9.6±5.0          |

BMI: Body mass index; FEV$_1$: Forced Expiratory Volume in the first second, BODE index: body-mass index, airflow obstruction, dyspnoea and exercise capacity index; mMRC: Modified British Medical Research Council; HADS: Hospital Anxiety and Depression Scale; GOLD II (FEV$_1$ ≥ 50% but < 80%), GOLD III (FEV$_1$ ≥ 30% but < 50%), GOLD IV (FEV$_1$ < 30%); n: number of patients.

https://doi.org/10.1371/journal.pone.0232587.t001

Table 2. Correlation matrix of 6-minute walking distance with lung function variables and HADS subscales for the 85 hospitalised COPD patients without major comorbidities.

|                | age | sex | BMI | FEV$_1$ | mMRC | BODE index $|$ | Education | HADS anxiety | HADS depression |
|----------------|-----|-----|-----|---------|------|----------------|-----------|--------------|----------------|
| 6 min walking distance | .087 | .135 | .218 | .600*** | -673*** | [-.795]$|$ | -.253 | -.441*** | -.523*** |
| Age            | .239* | .082 | .359*** | -.055 | -.112 | .107 | -.180 | -.133 |
| sex            | .327** | .194 | -.210 | -.171 | .215' | .096 | .036 |
| BMI            | .242* | -.193 | .379** | -.001 | -.171 | .215' | .096 | .065 |
| FEV$_1$        | .659*** | -.379** | -.133 | -.358*** | -.401*** | .001 | -.112 | -.180 |
| mMRC dyspnea  | -.639*** | -.741*** | -.133 | -.358*** | -.401*** | .001 | -.112 | -.180 |
| BODE Index $|$ | .708*** | -.133 | -.358*** | -.401*** | .001 | -.112 | -.180 | -.133 |
| Education      | .148 | .350** | .344* | .569*** | .248* | .124 | .248* | .569*** |

$^p < .05$

$^{**}p < .01$

$^{***}p < .001$

BMI: Body mass index; FEV$_1$: Forced Expiratory Volume in the first second, BODE index: body-mass index, airflow obstruction, dyspnoea and exercise capacity index; mMRC: Modified British Medical Research Council; HADS: Hospital Anxiety and Depression Scale.

$^*$ Note that BODE index contents categories of 6 min walking distance, of FEV$_1$, mMRC, and BMI. Therefore the BODE index is per se auto-correlated with 6 min walk, with FEV$_1$, with BMI, and with mMRC. As a consequence, the value has to be interpreted in this context.

https://doi.org/10.1371/journal.pone.0232587.t002
These findings are emphasized by the high effect size for lung function (\(f^2 = .717\)) and psychological variables (\(f^2 = .352\)). Socio-demographic variables (sex, age, and educational level) and the BMI could not explain any additional variance of the 6-minute walk test. The regression coefficients and the explained variance for each block are shown in Table 3.

The backward selection showed that FEV\(_1\) (\(\beta = .439, p = .0004\)) and HADS-depression (\(\beta = -.360, p = .003\)) alone explained 42% of the variance. Therefore, HADS-anxiety did not have an additional contribution (\(\beta = -.077, p = .597\)).

**Discussion**

The main finding of our study using for the first time quantitative standardised methods is that in addition to the lung function component (FEV\(_1\)), also psychological factors, mainly the depressive symptoms assessed with the HADS, correlate with results from the 6-minute walk test in patients with COPD. Indeed, nearly a quarter of the explained variance of the regression model, which included FEV\(_1\) and HADS subscales, can be attributed to depressive symptoms, and negatively affect the 6-minute walking distance.

It has been shown several times that depressive symptoms often occur as a comorbidity with COPD [40–43][44]. Upon surgical lung volume reduction in COPD patients, an important association was found between lung function improvement and amelioration of psychological factors [45] including a virtual normalization of HADS scores (not shown). Two existing meta-analyses report a prevalence rate of 24.6% and 27.1% in COPD patients with comorbid depression [41, 42]. Patients with severe COPD have an about 2.5-times higher risk of developing depression than control groups [46]. The prevalence rate of depressive symptoms in our cohort was 46% and therefore significantly higher than the prevalence rates found in literature. However, this may be due to the fact that our cohort exclusively consisted of hospitalised patients. However, depression prevalence or the prevalence of depressive symptoms likely also depend on the different tools to assess them [47, 48], on cut-off-points, on clinical settings such as COPD stage and on clinical evolution, i.e. clinical stability in terms of absence of exacerbation [48, 49]. Since mental comorbidities are often not diagnosed [50], it is therefore important to consider depression as a modifiable factor in patients with COPD. Orlandi
et al. also concluded that most studies typically analysed the symptoms of depression by questionnaires, without performing a clear professional diagnosis of depression in the studied patient groups [48, 51].

As the general level of activation in depressed patients is reduced [52], an explanation of the high significance of depression for results from the 6-minute walk test could be the lack of physical drive associated with depression. This means that these patients may lack the physical drive to walk as much as possible within 6 minutes. An anxious person, on the other hand, may still be motivated to walk as far as possible in this time frame.

Furthermore, the trend that depression is more associated with the progression of somatic diseases up to increased mortality than anxiety disorders can also be seen in studies with patients with cardiovascular disease [53–55]. Part of this observation could be due to the fact that depression is the more global construct of the two subscales.

Our study has important limitations. Firstly, it has a cross-sectional study design, which does not allow any clear causal conclusions to GOLD stages to be drawn. A longitudinal interventional format would be desirable to address the influence of GOLD stages. Secondly, our data cannot be generalized to all COPD patients, as only hospitalised patients in GOLD stages II to IV and having had an acute exacerbation, were recruited. Third, the 6-minute walk test was performed only once for each patient and thus represents an archetypical clinical situation. Repetitive intraindividual assessments would be preferable, also in order to be able to detect a possible causal link with time-series analyses, and mood and thus questionnaire results are also modified over time. Because of these limitations, the results of this study must be interpreted with caution.

In conclusion, the results of this study showed that psychological factors were associated with physical functional performance and therefore probably modulated physical functional performance in daily routine. It suggests that the relation between psychological factors and somatic measurements should be considered in clinical settings. At least part of them may be context-dependent. Indeed, COPD exacerbation leading to urgency hospitalisation represents a psychological stress associated with considerable mortality. Our study results may therefore differ from other, e.g. healthier study groups, or with other, e.g. clinically stable settings [48], or with much different 6-minute walking distances. Further studies should clarify the effects of factors leading to a reduction in depression, including medical and psychotherapeutic interventions [56], as well as physical activity, exercise and rehabilitation [57–60], which may also influence test results and may in parallel improve the quality of life and possibly the outcome of COPD patients [47].

**Author Contributions**

**Conceptualization:** Jürg Hamacher, Volker Köllner.

**Data curation:** Michèle Borgmann, Martina Ivanda.

**Formal analysis:** Michèle Borgmann.

**Funding acquisition:** Jürg Hamacher.

**Investigation:** Martina Ivanda.

**Methodology:** Michèle Borgmann, Volker Köllner.

**Project administration:** Michèle Borgmann, Martina Ivanda, Jürg Hamacher, Volker Köllner.

**Resources:** Martina Ivanda, Jürg Hamacher.

**Supervision:** Jürg Hamacher, Volker Köllner.
Validation: Michèle Borgmann.
Writing – original draft: Michèle Borgmann, Yalda Hadizamani.
Writing – review & editing: Markus Mohaupt, Robert Bals, Rudolf Lucas.

References

1. Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2007; 9(6–7):684–94. https://doi.org/10.1016/j.ejheart.2007.04.003 PMID: 17481947

2. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Annals of internal medicine. 2005; 143(4):282–92. https://doi.org/10.7326/0003-4819-143-4-200508160-00009 PMID: 16103472

3. Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? American heart journal. 1998; 136(3):449–57. https://doi.org/10.1016/s0002-8703(98)70219-4 PMID: 9736136

4. Macias A, Gavira JJ, Castano S, Alegria E, Garcia-Bolao I. Left ventricular pacing site in cardiac resynchronization therapy: clinical follow-up and predictors of failed lateral implant. European journal of heart failure. 2008; 10(4):421–7. https://doi.org/10.1016/j.ejheart.2008.02.019 PMID: 18395673

5. Rabelo ER, Ruschel K, Moreno H Jr., Rubira M, Consolim-Colombo FM, Irigoyen MC, et al. Venous endothelial function in heart failure: comparison with healthy controls and effect of clinical compensation. European journal of heart failure. 2008; 10(8):758–64. https://doi.org/10.1016/j.ejheart.2008.06.010 PMID: 18619901

6. Goscinska-Bis K, Bis J, Krejca M, Ulczok R, Szmagala P, Bochenek A, et al. Totally epicardial cardiac resynchronization therapy system implantation in patients with heart failure undergoing CABG. European journal of heart failure. 2008; 10(5):498–506. https://doi.org/10.1016/j.ejheart.2008.03.007 PMID: 18413295

7. Kokkinos P, Myers J, Kokkinos JP, Pittaras A, Narayan P, Manolis A, et al. Exercise capacity and mortality in black and white men. Circulation. 2008; 117(5):614–22. https://doi.org/10.1161/CIRCULATIONAHA.107.734764 PMID: 18212278

8. Beekman E, Mesters I, Hendriks EJM, Klaassen MPM, Gosselin R, van Schayck OCP, et al. Course length of 30 metres versus 10 metres has a significant influence on six-minute walk distance in patients with COPD: an experimental crossover study. Journal of Physiotherapy. 2013; 59(3):169–76. https://doi.org/10.1016/S1836-9553(13)70181-4 PMID: 23896332

9. Annegarn J, Spruit MA, Savelberg HH, Willems PJ, van de Bool C, Schols AM, et al. Differences in walking pattern during 6-min walk test between patients with COPD and healthy subjects. PLoS One. 2012; 7(5):e37329. https://doi.org/10.1371/journal.pone.0037329 PMID: 22624017

10. Cote CG, Casanova C, Marin JM, Lopez MV, Pinto-Plata V, de Oca MM, et al. Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J. 2008; 31(3):571–8. https://doi.org/10.1183/09031936.03.00034603 PMID: 17989117

11. Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly LJ, Celli BR. The 6-min walk distance, peak oxygen uptake, and mortality in COPD. Chest. 2007; 132(6):1778–85. https://doi.org/10.1378/chest.07-2050 PMID: 17925409

12. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004; 23(1):28–33. https://doi.org/10.1183/09031936.03.00034603 PMID: 14738227

13. Moy ML, Teylan M, Weston NA, Gagnon DR, Garshick E. Daily step count predicts acute exacerbations in a US cohort with COPD. PLoS One. 2013; 8(4):e60400. https://doi.org/10.1371/journal.pone.0060400 PMID: 23593211

14. Polkey MI, Spruit MA, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. American journal of respiratory and critical care medicine. 2013; 187(4):382–6. https://doi.org/10.1164/rcrm.201209-1596OC PMID: 23262518

15. Andrianopoulos V, Wouters EF, Pinto-Plata VM, Vanfleteren LE, Bakke PS, Franssen FM, et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respiratory medicine. 2015; 109(9):1138–46. https://doi.org/10.1016/j.rmed.2015.06.013 PMID: 26143282
16. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. European Respiratory Journal. 1993; 6(Suppl 16):5.

17. Casanova C, Cote CG, Marin JM, de Torres JP, Aguirre-Jaimé A, Mendez R, et al. The 6-min walking distance: long-term follow up in patients with COPD. Eur Respir J. 2007; 29(3):535–40. https://doi.org/10.1183/09031936.00071506 PMID: 17107991

18. Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respiratory medicine. 2010; 104(6):849–57. https://doi.org/10.1116/rcrm.201058-1630OC PMID: 20471326

19. Celli B, Tetzlaff K, Criner G, Polkey MI, Sciurba F, Casaburi R, et al. The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. American journal of respiratory and critical care medicine. 2016; 194(12):1483–93. https://doi.org/10.1164/rccm.201508-1653OC PMID: 27332504

20. Mendoza L, Horta P, Espinoza J, Aguilera M, Balmaceda N, Castro A, et al. Pedometers to enhance physical activity in COPD: a randomised controlled trial. Eur Respir J. 2015; 45(2):347–54. https://doi.org/10.1183/09031936.00084514 PMID: 25261324

21. Carter R, Holiday DB, Nwasuruba C, Stocks J, Grothues C, Tiep B. 6-minute walk work for assessment of functional capacity in patients with COPD. Chest. 2003; 123(5):1408–15. https://doi.org/10.1378/chest.123.5.1408 PMID: 12740255

22. Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N, Loukides S. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest. 2007; 132(1):164–9. https://doi.org/10.1378/chest.06-2789 PMID: 17505043

23. Huijsmans RJ, de Haan A, ten Hacken NN, Straver RV, van't Hul AJ. The clinical utility of the GOLD classification of COPD disease severity in pulmonary rehabilitation. Respiratory medicine. 2008; 102(1):162–71. https://doi.org/10.1016/j.rmed.2007.07.006 PMID: 17881207

24. Lee YK, Oh YM, Lee JH, Kim EK, Lee JH, Kim N, et al. Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography. Lung. 2008; 186(3):157–65. https://doi.org/10.1007/s00408-008-9071-0 PMID: 18351420

25. Carr SJ, Goldstein RS, Brooks D. Acute exacerbations of COPD in subjects completing pulmonary rehabilitation. Chest. 2007; 132(1):127–34. https://doi.org/10.1378/chest.07-0269 PMID: 17475631

26. Agusti AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2002; 166(4):485–9. https://doi.org/10.1164/rccm.2108013 PMID: 12186825

27. Montes de Oca M, Torres SH, De Sanctis J, Mata A, Hernandez N, Talamo C. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J. 2005; 26(3):390–7. https://doi.org/10.1183/09031936.05.00107404 PMID: 16135718

28. Ingle L, Rigby AS, Nabb S, Jones PK, Clark AL, Cleland JG. Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease. European journal of heart failure. 2006; 8(3):321–5. https://doi.org/10.1016/j.ejheart.2005.08.006 PMID: 16266825

29. Serra AJ, de Carvalho PdTC, Lanza F, de Amorim Flandes C, Silva SC, Suzuki FS, et al. Correlation of six-minute walking performance with quality of life is domain-and gender-specific in healthy older adults. PLoS one. 2015; 10(2):e0117359. https://doi.org/10.1371/journal.pone.0117359 PMID: 25695668

30. Borgmann M, Linnemann T, Schönhofer B, Ott SR, Bernardy K, Stammberger U, et al. Krankheitserleben, Partnerschaft und Sexualität bei Patienten mit COPD. Experience of Disease, Relationship and Sexuality in Patients with COPD. Z Psychosom Med Psychother. 2019:258–72.

31. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). https://goldcopd.org/gold-reports/; 2020.

32. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31(2):416–69. https://doi.org/10.1183/09031936.00099306 PMID: 18238951

33. Zigmond AS, Snith RP. The hospital anxiety and depression scale. Acta psychiatraca Scandinavica. 1983; 67(6):361–70. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x PMID: 6880820

34. Petermann F. Hospital Anxiety and Depression Scale, Deutsche Version (HADS-D). Zeitschrift für Psychiatrie, Psychologie und Psychotherapie. 2015.

35. Marin JM, Carrizo SJ, Casanova C, Martinez-Cambor P, Soriano JB, Agusti AG, et al. Prediction of risk of COPD exacerbations by the BODE index. Respiratory medicine. 2009; 103(3):373–8. https://doi.org/10.1016/j.rmed.2008.10.004 PMID: 19013781
36. Bestall J, Paul E, Garrod R, Garnham R, Jones P, Wedzicha J. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54(7):581–6. https://doi.org/10.1136/thx.54.7.581 PMID: 10377201

37. Döring N, Bortz J. Forschungsmethoden und Evaluation in den Sozial- und Humanwissenschaften. 5 ed. Berlin, Heidelberg: Springer; 2016.

38. Cohen J. Statistical power analysis for the behavioral sciences. 2 ed. New Jersey: Lawrence Erlbaum Associates; 1988.

39. Cohen J. A power primer. Psychol Bull. 1992; 112(1):155–9. https://doi.org/10.1037/0033-2909.112.1.155 PMID: 19565683

40. Schneider C, Jick SS, Bothner U, Meier CR. COPD and the risk of depression. Chest. 2010; 137 (2):341–7. https://doi.org/10.1378/chest.09-0614 PMID: 19801582

41. Matte DL, Pizzichini MM, Hoepers AT, Diaz AP, Karloch M, Dias M, et al. Prevalence of depression in COPD: A systematic review and meta-analysis of controlled studies. Respiratory medicine. 2016; 117:154–61. https://doi.org/10.1016/j.rmed.2016.06.006 PMID: 27492526

42. Zhang MW, Ho RC, Cheung MW, Fu E, Mak A. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2011; 33(3):217–23. https://doi.org/10.1016/j.genhosppsic.2011.03.009 PMID: 21601717

43. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest Journal. 2008; 134(suppl):43–56.

44. Lou P, Zhu Y, Chen P, Zhang P, Yu J, Zhang N, et al. Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC pulmonary medicine. 2012; 12:53–. https://doi.org/10.1186/1471-2466-12-53 PMID: 22958576

45. Hamacher J, Büchi S, Georgescu CL, Stammberger U, Thurnheer R, Bloch KE, et al. Improved quality of life after lung volume resection surgery. European Respiratory Journal. 2002; 19(1):54. https://doi.org/10.1183/09031936.02.00462001 PMID: 11843327

46. Van Manen J, Bindels P, Dekker F, IJzermans C, Van der Zee J, Schade E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax. 2002; 57(5):412–6. https://doi.org/10.1136/thorax.57.5.412 PMID: 11978917

47. Al-shair K, Dockry R, Mallia-Milanes B, Kolsum U, Singh D, Vestbo J. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respiratory medicine. 2009; 103(10):1572–9. https://doi.org/10.1016/j.rmed.2008.11.021 PMID: 19560330

48. Orlandi LdCL, Pinho JF, Murad MGR, Rocha FL, Rodrigues-Machado MG. Depression diagnosed by the mini international neuropsychiatric interview plus (MINI) in patients with chronic obstructive pulmonary disease: relationship with functional capacity and quality of life. BMC research notes. 2016; 9:65–. https://doi.org/10.1186/s13104-016-1883-z PMID: 26847708

49. Jennings JH, Digiovine B, Obeid D, Frank C. The association between depressive symptoms and acute exacerbations of COPD. Lung. 2009; 187(2):128–35. https://doi.org/10.1007/s00408-009-9135-9 PMID: 19189840

50. von Leupoldt A. COPD und psychische Komorbiditäten. Der Pneumologe. 2016; 13(3):156–65.

51. Panagioti M, Scott C, Blakemore A, Coventry PA. Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease. 2014; 9:1289–306. https://doi.org/10.2147/COPD.S72073 PMID: 25419126

52. Galper DI, Trivedi MH, Barlow CE, Dunn AL, Kampert JB. Inverse association between physical inactivity and mental health in men and women. Medicine & Science in Sports & Exercise. 2006; 38(1):173–8.

53. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastasso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World psychiatry: official journal of the World Psychiatric Association (WPA). 2017; 16(2):163–80.

54. Meijer A, Zuideveld M, de Jonge P. Depression as a non-causal variable risk marker in coronary heart disease. BMC medicine. 2013; 11:130. https://doi.org/10.1186/1741-7015-11-130 PMID: 23676144

55. Albus C, Waller C, Fritzsche K, Gunold H, Haas M, Hamann B, et al. Bedeutung von psychosozialen Faktoren in der Kardiologie–Update 2018. Der Kardiologe. 2018; 12(5):312–31.

56. Pumar MI, Roll M, Fung P, Rolls TA, Walsh JR, Bowman RV, et al. Cognitive behavioural therapy (CBT) for patients with chronic lung disease and psychological comorbidities undergoing pulmonary...
rehabilitation. J Thorac Dis. 2019; 11(Suppl 17):S2238–s53. https://doi.org/10.21037/jtd.2019.10.23 PMID: 31737351

57. Kozora E, Tran ZV, Make B. Neurobehavioral improvement after brief rehabilitation in patients with chronic obstructive pulmonary disease. Journal of cardiopulmonary rehabilitation. 2002; 22(6):426–30. https://doi.org/10.1097/00008483-200221000-00008 PMID: 12464831

58. Paz-Díaz H, Montes de Oca M, López JM, Celli BR. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. American journal of physical medicine & rehabilitation. 2007; 86(1):30–6.

59. Schuler M, Strohmayer M, Mühlig S, Schwaighofer B, Wittmann M, Faller H, et al. Assessment of depression before and after inpatient rehabilitation in COPD patients: Psychometric properties of the German version of the Patient Health Questionnaire (PHQ-9/PHQ-2). Journal of affective disorders. 2018; 232:268–75. https://doi.org/10.1016/j.jad.2018.02.037 PMID: 29499510

60. Lavoie KL, Sedeno M, Hamilton A, Li PZ, De Sousa D, Troosters T, et al. Behavioural interventions targeting physical activity improve psychocognitive outcomes in COPD. ERJ open research. 2019; 5(4).